Aurinia Pharmaceuticals Inc. AUPH
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis ("LN"). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor ("BAFF") and a proliferation-inducing ligand ("APRIL") for the potential treatment of autoimmune diseases.
Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States ("U.S."), and Aurinia sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), for the European and Japanese market.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- U.S.
- Japan
| Region | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| U.S. | $263.8M | $210.1M | $158.0M |
| Japan | $19.2M | $25.0M | $17.6M |
As the company reported it, from the “Segment Information and Geographic Data - Schedule of Revenue by Geographic Location (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M | $45.6M | $50.1M | $318.0K | $463.0K | $418.0K | $173.0K |
| Cost of revenue | $32.7M | $28.2M | $14.1M | $5.7M | $1.1M | $0 | $0 | — | — | — |
| Gross profit | $250.4M | $206.9M | $161.4M | $128.4M | $44.5M | $50.1M | $318.0K | — | — | — |
| R&D | $32.5M | $20.8M | $49.6M | $45.0M | $51.1M | $50.3M | $52.9M | $41.4M | — | — |
| SG&A | $101.8M | $172.0M | $195.0M | $196.4M | $173.5M | $97.3M | $22.3M | $13.7M | — | — |
| Total operating expenses | $178.1M | $239.8M | $267.2M | $245.5M | $226.3M | $154.4M | $91.3M | $55.7M | — | — |
| Operating income | $104.9M | -$4.7M | -$91.7M | -$111.5M | -$180.7M | -$104.3M | -$90.9M | -$55.2M | -$46.9M | -$25.0M |
| Interest expense | $4.3M | $4.8M | $2.8M | $0 | $0 | — | — | — | — | — |
| Pre-tax income | $114.2M | $7.4M | -$77.5M | -$106.4M | -$180.2M | -$102.8M | -$88.2M | -$53.0M | — | — |
| Income tax | $173.0M | $1.7M | $551.0K | $1.8M | $760.0K | $94.0K | $144.0K | $73.0K | — | — |
| Net income | $287.2M | $5.8M | -$78.0M | -$108.2M | -$181.0M | -$102.7M | -$88.4M | -$53.1M | -$70.8M | -$23.3M |
| EPS, basic | 2.14 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 | -0.95 | — | — | — |
| EPS, diluted | 2.07 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 | -0.95 | -0.63 | — | — |
| Shares, diluted (wtd. avg.) | 138.7M | 146.2M | 143.2M | 141.9M | 129.4M | 118.5M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $80.2M | $83.4M | $48.8M | $94.2M | $231.9M | $272.4M | $306.0M | $118.0M | $165.6M | — |
| Inventory | $45.7M | $39.2M | $39.7M | $24.8M | $19.3M | $13.9M | $0 | — | — | — |
| Total current assets | $492.0M | $446.6M | $424.8M | $442.5M | $513.3M | $419.4M | $315.1M | — | — | — |
| Property, plant and equipment | $2.1M | $2.7M | $3.4M | $3.6M | $4.4M | $4.8M | $93.0K | — | — | — |
| Other intangibles | $3.8M | $4.4M | $5.0M | $6.4M | $8.4M | $9.3M | $8.9M | — | — | — |
| Total assets | $751.6M | $550.6M | $548.1M | $470.9M | $543.4M | $463.7M | $324.3M | $145.9M | $189.8M | $57.0M |
| Accounts payable | $3.3M | $5.2M | $4.3M | $40.0M | $34.9M | $24.8M | $11.2M | — | — | — |
| Total current liabilities | $93.7M | $97.8M | $77.2M | $46.1M | $40.6M | $32.0M | $11.3M | — | — | — |
| Total liabilities | $170.3M | $173.2M | $170.1M | $65.4M | $64.3M | $55.9M | $25.7M | — | — | — |
| Retained earnings | -$649.4M | -$936.6M | -$942.3M | -$864.3M | -$756.1M | -$575.2M | -$472.5M | — | — | — |
| Total equity | $581.3M | $377.5M | $378.0M | $405.4M | $479.1M | $407.8M | $298.6M | $135.7M | $177.9M | $36.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $135.7M | $44.4M | -$33.5M | -$79.5M | -$157.7M | -$69.9M | -$63.6M | -$51.6M | — | — |
| Depreciation and amortisation | $19.4M | $19.4M | $11.6M | $2.7M | $2.8M | $1.4M | $33.0K | $20.0K | — | — |
| Stock-based compensation | $14.7M | $31.6M | $45.3M | $32.3M | $31.2M | $17.5M | $7.4M | $6.9M | — | — |
| Investing cash flow | -$32.8M | $39.3M | -$6.7M | -$60.6M | -$103.9M | -$158.2M | $7.8M | -$65.0K | — | — |
| Financing cash flow | -$106.1M | -$49.1M | -$5.1M | $2.4M | $221.1M | $194.4M | $243.9M | $4.0M | — | — |
| Buybacks | $98.2M | $40.2M | $0 | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001600620-26-000039.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $173.0K | $418.0K | $463.0K | $318.0K | $50.1M | $45.6M | $134.0M | $175.5M | $235.1M | $283.1M |
| Gross profit | — | — | — | $318.0K | $50.1M | $44.5M | $128.4M | $161.4M | $206.9M | $250.4M |
| Net income | -$23.3M | -$70.8M | -$53.1M | -$88.4M | -$102.7M | -$181.0M | -$108.2M | -$78.0M | $5.8M | $287.2M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |